Skip to main content
Signal8

Rapid Therapeutic Science Laboratories, Inc. (RTSL)

Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.

Sector: Medical - Pharmaceuticals

Industry: Medical - Pharmaceuticals

Rapid Therapeutic Science Laboratories, Inc. logo

Rapid Therapeutic Science Laboratories, Inc.

OTC:RTSLHealthcare
$0.0001
CLOSED
Mkt Cap$883
EV-
Float3.69M
O/S8.83M
VOL213 sh
$ Vol$0
RVOL0.41×
Inst Own-
Net Cash/Sh-
Dilution
Financials Summary
Revenue$0
Net Income-$183K
Total Assets$968K
Free Cash Flow-$1.19M
Debt & Equity
Debt 951%
Total Debt$3.45M
Total Equity-$3.08M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
  1. 1:25Reverse split
    Mar 31, 202225 shares → 1
Balance Sheet Details
Assets$968K
Liabilities$4.05M
Accounts Receivable$0
Accounts Payable$212K
Inventory$175K
PP&E (Net)$623K
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2024FY 2022FY 2021FY 2019FY 2017FY 2016FY 2015FY 2014FY 2013
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2024-12-312022-12-312021-12-312020-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
Revenue$0$0$534$9K$0$0$0$0$0
YoY Growth---94.2%------
Cost of Revenue$24K$0$200$7K$0$0$0$0$0
Gross Profit-$24K$0$334$2K$0$0$0$0$0
Gross Margin--62.5%21.7%-----
Research and Development$0$0$0$0$0$0$0$0$0
Selling, General, and Administrative$59K$1.24M$2.11M$170K$136K$22K$12K$12K$19K
Other$0$24K$56K$0$16K$0$0$0$0
Total Operating Expenses$59K$1.26M$2.17M$170K$152K$22K$12K$12K$19K
Operating Income (EBIT)-$83K-$1.26M-$2.17M-$170K-$2.52M-$22K-$12K-$12K-$19K
Operating Margin---406422.3%-1856.8%-----
Interest Expense$100K$1.9M$1.32M$181K$29K$0$0$0$0
Interest Income$0$0$0$0$0$0$0$0$0
Other Income (Expense)-$100K-$531K-$698K$1K-$2.37M$0$0$0$0
Income Before Tax (EBT)-$183K-$1.79M-$2.87M-$349K-$2.55M-$22K-$12K-$12K-$19K
Income Tax Expense$0-$101K$1.33M-$1K$29K$0$0$0$0
Net Income-$183K-$1.69M-$4.2M-$349K-$2.55M-$22K-$12K-$12K-$19K
Net Income Margin---786015.7%-3817.1%-----
Supplementary Data
EPS-0.01-0.22-0.55-7.24-25.88-0.20-0.11-0.11-0.17
Diluted EPS-0.01-0.22-0.55-7.24-25.88-0.20-0.11-0.11-0.17
Weighted Average OS19.30M7.75M7.63M48,16098,643108,400108,400108,400108,400
EBITDA-$59K-$1.24M-$2.11M-$132K-$136K$22K-$12K-$12K-$19K
EBITDA Margin---395961.8%-1446.4%-----
Balance Sheet
PeriodFY 2024FY 2022FY 2021FY 2019FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2024-12-312022-12-312021-12-312020-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-31
Assets
Current Assets
Cash and Cash Equivalents$0$0$192K$136K$12K$7K$9K$10K$19K$32K
Short-Term Investments$0$0$0$0$0$0$0$0$0$0
Cash and Short-Term Investments$0$0$192K$136K$12K$7K$9K$10K$19K$32K
Accounts Receivable$0$0$0$0$0$0$0$0$0$0
Inventory$175K$175K$175K$0$0$0$0$0$0$0
Other Current Assets$0$0$52K$0$10K$0$750$750$4K$10K
Total Current Assets$175K$233K$419K$142K$22K$7K$10K$11K$23K$42K
Long-Term Assets
Property, Plant & Equipment Net$623K$1.85M$1.61M$0$0$0$0$0$0$0
Goodwill$0$0$0$0$0$0$0$0$0$0
Intangible Assets$0$170K$170K$303K$4K$0$0$0$0$0
Long-Term Investments$0$0$0$0$0$0$0$0$0$0
Deferred Tax Assets$0$0$0$0$0$0$0$0$0$0
Other Long-Term Assets$0$0$0$0$0$0$0$0$0$0
Total Long-Term Assets$793K$2.02M$1.78M$303K$4K$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Assets$968K$2.25M$2.2M$445K$26K$7K$10K$11K$23K$42K
Liabilities
Current Liabilities
Accounts Payable$212K$891K$465K$65K$15K$300$1K$0$0$0
Short-Term Debt$3.45M$3.3M$1.38M$907K$645K$30K$0$0$0$0
Current Income Tax Payable$0$0$0$0$0$0$0$0$0$0
Current Unearned Revenue$0$0$0$32K$0$0$0$0$0$0
Other Current Liabilities$393K$549K$1.09M$0$0$0$0$0$0$0
Total Current Liabilities$4.05M$4.97M$3.05M$1.49M$689K$30K$11K$0$0$0
Long-Term Liabilities
Long-Term Debt$0$150K$150K$315K$2.2M$0$0$0$0$0
Long-Term Unearned Revenue$0$0$0$0$0$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0$0$0$0$0$0
Other Long-Term Liabilities$0$0$0$0$0$0$0$0$0$0
Total Long-Term Liabilities$0$430K$529K$315K$2.2M$0$0$0$0$0
Other Liabilities$0$0$0$0$0$0$0$0$0$0
Total Liabilities$4.05M$5.4M$3.58M$1.81M$2.89M$30K$11K$0$0$0
Stockholders' Equity
Preferred Stock$0$0$0$0$0$0$0$0$0$0
Common Stock$19K$8K$8K$160K$1K$3K$3K$3K$3K$3K
Retained Earnings-$10.47M-$10.32M-$8.52M-$3.6M-$2.63M-$75K-$53K-$41K-$29K-$10K
Comprehensive Income & Other$0$0$0$0$0$0$0$0$0$0
Other Stockholders' Equity$7.37M$7.17M$7.13M$2.08M-$236K$49K$49K$49K$49K$49K
Total Equity-$3.08M-$3.14M-$1.38M-$1.36M-$2.86M-$23K-$1K$11K$23K$42K
Minority Interest$0$0$0$0$0$0$0$0$0$0
Total Liabilities and Equity$968K$2.25M$2.2M$445K$26K$7K$10K$11K$23K$42K
Supplementary Data
Total Debt$3.45M$3.83M$1.99M$1.22M$2.85M$30K$0$0$0$0
Net Debt$3.45M$3.83M$1.79M$1.09M$3K$23K-$9K-$10K-$19K-$32K
Cash Flow Statement
PeriodFY 2022FY 2021FY 2019FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
CurrencyUSDUSDUSDUSDUSDUSDUSDUSDUSD
Period Ending2022-12-312021-12-312020-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-31
Operating Activities
Net Income-$1.79M-$2.87M-$349K-$2.55M-$22K-$12K-$12K-$19K-$10K
Depreciation & Amortization$24K$56K$38K$16K$22K$0$0$0$0
Deferred Income Tax$0-$632K$7K$0$0$0$0$0$0
Stock-Based Compensation$20K$20K$43K$7K$0$0$0$0$0
Changes in Working Capital:
  Accounts Receivable$0$0$6K$0$0$0$0$0$0
  Inventory$0$12K-$6K$0$0$0$0$0$0
  Accounts Payable$128K$82K$5K$15K-$977$1K$0$0$0
  Other Working Capital$73K-$27K$194K$15K$750$0$4K$6K-$10K
Total Working Capital Change$200K$67K$199K$29K-$227$1K$4K$6K-$10K
Other Non-Cash Items$399K$1.15M-$45K$2.37M-$22K$0$0$0$0
Net Cash from Operating-$1.15M-$2.21M-$107K-$130K-$22K-$11K-$9K-$13K-$20K
Investing Activities
Capital Expenditures-$39K-$293K-$155K-$39K$0$0$0$0$0
Acquisitions$0$0$0$0$0$0$0$0$0
Purchases of Investments$0$0$0$0$0$0$0$0$0
Sales of Investments$0$0$0$0$0$0$0$0$0
Other Investing Activities$0$0$0$0$0$0$0$0$0
Net Cash from Investing-$39K-$293K-$155K-$39K$0$0$0$0$0
Financing Activities
Debt Repaid---------
Common Stock Issuance$0$585K$75K$1K$0$0$0$0$0
Common Stock Repurchases$0$0$0$0$0$0$0$0$0
Dividends Paid$0$0$0$0$0$0$0$0$0
Other Financing Activities$1.29M$0$21K$172K$20K$10K$0$0$50K
Net Cash from Financing$998K$2.19M$96K$173K$20K$10K$0$0$50K
Forex Effect$0$0$155K$0$0$0$0$0$0
Net Change in Cash-$192K-$307K-$11K$5K-$2K-$743-$9K-$13K$30K
Supplementary Data
Operating Cash Flow-$1.15M-$2.21M-$107K-$130K-$22K-$11K-$9K-$13K-$20K
Capital Expenditure-$39K-$293K-$155K-$39K$0$0$0$0$0
Free Cash Flow-$1.19M-$2.5M-$262K-$168K-$22K-$11K-$9K-$13K-$20K
Cash at Beginning$192K$499K$12K$7K$9K$10K$19K$32K$0
Cash at End$0$192K$1K$12K$7K$9K$10K$19K$30K